No photo of Josien Janssen

Josien Janssen

20202020

Research activity per year

If you made any changes in Pure these will be visible here soon.
  • Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

    Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M. & 15 others, van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B., Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) & Swiss Group for Clinical Cancer Research (SAKK), Oct 2020, In: Leukemia. 34, 10, p. 2820-2820 1 p., 2820.

    Research output: Contribution to journalErratum / corrigendum / retractionsAcademic

    Open Access